RecruitingNot ApplicableNCT06041620
Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells
A Study to Evaluate the Efficacy and Safety of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells in Transfusion-dependent β Thalassemia Patients
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Enrollment
2 participants
Start Date
Aug 31, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
This is a single-arm, open, single-injection exploratory clinical study with two transfusion-dependent β thalassemia (β-TDT) participants planned to enroll.
Eligibility
Min Age: 3 YearsMax Age: 35 Years
Inclusion Criteria8
- Age 3-35 years old (inclusive), male or female;
- The subject and/or his/her legally recognized representative/parent/guardian fully understands the study and all information related to the study and has signed the informed consent form;
- Clinical diagnosis of transfusion-dependent β-thalassemia (TDT) with a blood transfusion record within 2 years (inclusive) prior to screening showing a history of ≥ 10 units (U)/kg/year (or ≥ 100 mL/kg/year) or ≥ 8 times/year of suspended RBC transfusions in at least 1 consecutive 12-month period;
- Karnofsky score (for subjects aged ≥ 16 years) or Lansky score (for subjects aged < 16 years) of ≥ 80;
- Subjects in stable disease state who are eligible for hematopoietic stem cell transplantation as per investigator's judgment;
- Access to diagnosis and treatment records issued by medical professional institutions within 2 years prior to screening, including the records of blood transfusions, hematology, serum chemistry, and other examinations;
- Willing and able to comply with study procedures, with good compliance, and willing to receive and complete the follow-up study with a duration of at least 2 years;
- Subjects of childbearing potential (including female subjects of childbearing potential and male subjects whose partners are of childbearing potential) must use effective contraception within 12 months of treatment.
Exclusion Criteria15
- Diagnosis of associated α-thalassemia: > 1 alpha chain deletion or alpha gene functional defect;
- Have available HLA-fully matched donors and acceptable for allogeneic hematopoietic stem cell transplantation;
- Irregular antibody or platelet antibody positive;
- Prior allogeneic bone marrow transplantation or gene therapy;
- Subjects with clinically significant and active bacterial, viral, fungal, or parasitic infection as determined by the investigator at screening, including but not limited to those with positive etiology of human immunodeficiency virus (HIV-1/2), human cytomegalovirus (HCMV-DNA), Epstein-Barr virus (EBV-DNA), or Treponema pallidum antibody (TP-Ab), or with previous hepatitis B or C infection;
- Subjects with an injury of major organs
- Contraindications for hematopoietic stem cell collection and poor collection efficiency judged by the investigator;
- Contraindications to the clinical investigational product and its excipients, G-CSF (hematopoietic stem cell mobilization), plerixafor (hematopoietic stem cell mobilization), busulfan (myeloablation), and other drugs;
- Participation within 3 months prior to screening or current participation in another interventional clinical study;
- History or family history of malignancy or myeloproliferative disorder;
- History of uncontrollable epilepsy, mental disorder, or other psychiatric disorders;
- Abuse of psychoactive substance, drug, or alcohol within 6 months prior to enrollment;
- Pregnant or breastfeeding females;
- Other diseases or reasons that interfere with study procedures;
- Any other conditions that the investigator deems unsuitable for the subject's participation in the study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALVGB-Ex01
CRISPR-Cas12b editing hematopoietic stem cells
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06041620
Related Trials
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
NCT057364196 locations
Growth Evaluation, Health Promotion, and Clinical Management in Children and Adolescents With Thalassemia
NCT069319121 location
Effect of Incentive Respiratory Training on Pulmonary Functions and Functional Capacity in Children With B-thalassemia Major
NCT071127031 location
Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia
NCT064906271 location
Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thalassemia
NCT057761731 location